Indegene Limited operates as a digital-first life sciences commercialization company in India, the United States, Europe, and internationally. It operates through three segments: Enterprise Medical Solutions, Enterprise Commercial Solutions, Omnichannel Activation & Others. The company develops biotech and medical device for biopharmaceutical, emerging biotech, and medical device companies. It also offers enterprise commercial, medical, and clinical solutions; and omnichannel activation solutions. In addition, the company operates NEXT technology platforms. Further, it provides analytics, technology, commercial, medical, regulatory, and safety services to life science and healthcare organizations. Indegene Limited was incorporated in 1998 and is based in Bengaluru, India.
| Current Price | ₹518.45 |
|---|---|
| Market Cap | ₹12,443 Cr |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Life Sciences Tools and Services |
| Sub-Industry | Life Sciences Tools and Services |
| P/E Ratio | 31.2 |
| Return on Equity | 13.94% |
| 52-Week Range | ₹414.00 – ₹620.20 |
| Beta (1Y) | 0.52 |
| Dividend Yield | 0.43% |
1. Enterprise Medical Solutions-26.5% 2. Enterprise Commercial Solutions-70.1% 3. Others-3.4%
Indegene Ltd is trading at ₹518.45, with a market capitalisation of ₹12,443 Cr.
Indegene Ltd operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Life Sciences Tools and Services space (Life Sciences Tools and Services).
Indegene Ltd has a P/E of 31.2 and a return on equity of 13.94%.